MDA-MB-468 Metastatic Tumor Model Service for Breast Cancer

The MDA-MB-468 Metastatic Tumor Model Service for Breast Cancer provides a genetically defined human triple-negative xenograft distinguished by EGFR amplification and PTEN loss, offering an exceptional testbed for PI3K/AKT pathway and DNA-damage response therapeutics. Alfa Cytology delivers this model as a complete preclinical package — authenticated cell banking, immunodeficient host preparation, subcutaneous or orthotopic implantation with Matrigel support, scheduled efficacy monitoring, and terminal histological and molecular endpoint analysis — enabling breast cancer programs to interrogate pathway-specific hypotheses with rigor.

Overview of MDA-MB-468 Metastatic Tumor Model for Breast Cancer

MDA-MB-468 is a human breast adenocarcinoma cell line isolated in 1977 by R. Cailleau and colleagues from the pleural effusion of a 51-year-old woman with metastatic disease, and it remains the canonical representative of the basal-like subtype of triple-negative breast cancer (TNBC). Unlike the mesenchymal, highly invasive MDA-MB-231 line, MDA-MB-468 retains epithelial architecture and unusually high E-cadherin expression, yet is defined by two powerful genomic lesions: massive amplification of the epidermal growth factor receptor (EGFR) gene — on the order of one million receptor molecules per cell — and homozygous loss of the PTEN tumor suppressor through a splice-donor mutation. PTEN loss removes the brake on phosphoinositide 3-kinase signaling, driving constitutive AKT/mTOR pathway activation, while homozygous TP53 (R273H) mutation and RB1 deletion compound its cell-cycle dysregulation. The combination of EGFR overexpression with PI3K-pathway hyperactivation — despite a PIK3CA wild-type background — has made MDA-MB-468 the reference system for dissecting receptor-tyrosine-kinase cross-talk with the AKT/mTOR cascade in vitro.

Fig 1. Histopathological evaluation of the MDA-MB-468 xenograft model after HER3-targeted NIR-PIT: H&E staining shows characteristic acute necrotic cell death (arrowheads: ballooned cells) in treated MDA-MB-468 tumors, with pan-cytokeratin immunofluorescence confirming tumor cell distribution. (Kano, Makoto, et al., 2026)

As a xenograft in immunodeficient mice, MDA-MB-468 cells reliably form poorly differentiated, densely proliferative solid tumors that reproduce the aggressive growth, central necrosis, and therapeutic resistance typical of basal-like TNBC, and the model has become a standard efficacy benchmark for mechanistically targeted agents: PARP inhibitors such as olaparib markedly suppress MDA-MB-468 xenograft growth, EGFR-directed inhibitors and anti-EGFR antibody–drug conjugates are routinely tested against this line, and AKT/mTOR antagonists are validated in precisely the PTEN-null context the model provides. Tumors can be established subcutaneously or orthotopically in the mammary fat pad, with typical inocula of 1–2 × 10⁶ cells in a Matrigel-supported suspension, and luciferase-tagged derivatives (MDA-MB-468-Luc; GFP-labeled MDA-MB-468LN) extend the platform to imaging-guided studies in vivo. For preclinical teams seeking a TNBC model with a clean, druggable genetic rationale, MDA-MB-468 occupies a unique position among human breast cancer xenografts.

Cell Line Information: MDA-MB-468

MDA-MB-468 (synonyms: MDAMB-468; MB-468) is among the best-documented TNBC lines and a member of the NCI-60 anticancer drug screen panel. Its defining characteristics are summarized below.

Our Services

Alfa Cytology maintains authenticated, mycoplasma-free MDA-MB-468 stocks — including luciferase and GFP-labeled derivatives — within optimized L-15 and CO₂-independent culture workflows, and operates established athymic nude, SCID, and NOD/SCID xenograft colonies for this model. Whether the objective is a rapid subcutaneous efficacy screen or an orthotopic program with molecular endpoint panels, each study is executed under strict randomization and quality control with clear statistical reporting.

Workflow of MDA-MB-468 Metastatic Tumor Model Construction

Establishing an MDA-MB-468 xenograft study requires attention to the line’s CO₂-independent culture preferences and Matrigel-supported engraftment. The stages below describe how the model is constructed and evaluated:

1. Cell Line Preparation: MDA-MB-468 cells are authenticated by STR profiling, confirmed mycoplasma-free, and expanded at controlled passage in L-15 or an approved alternative medium; reporter derivatives are verified for label stability.
2. Host Acclimatization and Allocation: Female immunodeficient mice (athymic nude, SCID, or NOD/SCID, depending on study requirements) are acclimatized and randomly assigned to experimental groups.
3. Tumor Cell Implantation: High-viability single-cell suspensions (typically 1–2 × 10⁶ cells in 120–150 µL) are blended with Matrigel and injected subcutaneously into the flank, or 2 × 10⁶ cells are implanted into the mammary fat pad for orthotopic growth.
4. Tumor Establishment Monitoring: Implant sites are monitored until measurable tumors form; caliper-based volume tracking, body weight, and clinical status are recorded on a fixed schedule.
5. Randomization and Dosing: Animals are re-randomized once tumors reach the predefined size (e.g., approximately 150–200 mm³), and dosing with vehicle, benchmark agents (e.g., olaparib or pathway inhibitors), or test articles begins.
6. In-Life Follow-Up: Tumor growth, body weight, and tolerability are tracked throughout the dosing period; luciferase-labeled cohorts may be imaged in vivo for longitudinal burden assessment.
7. Terminal Analysis: At necropsy, tumors are excised, weighed, and photographed; tissues are fixed for hematoxylin and eosin histology, processed for immunohistochemistry (e.g., EGFR, PTEN, phospho-AKT), or snap-frozen for molecular analysis.
8. Data Analysis and Reporting: Tumor-growth inhibition, response rates, and molecular endpoint data are statistically evaluated and consolidated into a final study report.

Fig 2. MDA-MB-468 Metastatic Tumor Model construction workflow.

Case Study-MDA-MB-468 Metastatic Tumor Model Development

In a representative preclinical collaboration, Alfa Cytology established the MDA-MB-468 xenograft model for a sponsor advancing a targeted agent in triple-negative breast cancer. The engagement encompassed expansion and Matrigel-supported implantation of authenticated cells in immunodeficient hosts, balanced allocation of vehicle and treatment arms, scheduled monitoring of tumor growth and animal tolerability, and terminal tumor collection with histological and molecular endpoint analysis — producing an integrated dataset that informed the client’s preclinical development planning. Case formats can be arranged around single-agent efficacy, pathway-inhibitor benchmarking, ADC evaluation, or combination strategies as program objectives dictate.

Why Choose Alfa Cytology?

Alfa Cytology offers both the model resources and the pathway-level insight needed to extract maximum value from this genetically defined TNBC xenograft. Reasons sponsors select our MDA-MB-468 service include:

• Proven execution with MDA-MB-468 across nude, SCID, and NOD/SCID host formats.
• Genotype-aware study design exploiting the EGFR-amplified, PTEN-null background for mechanism-driven hypotheses.
• In-house luciferase and GFP-labeled derivatives supporting imaging-guided programs in vivo.
• Matrigel-supported implantation expertise that ensures high and consistent engraftment rates.
• Molecular endpoint capability including phospho-AKT and pathway-marker immunohistochemistry.
• Strict quality control and clear, statistically interpreted reporting on agreed timelines.

Contact Us

Looking for a triple-negative breast cancer model with a clean genetic rationale for your next preclinical study? The MDA-MB-468 team at Alfa Cytology is ready to help you design it. Reach out to us to discuss your program, or contact us today for a customized quotation and timeline.

For research use only. Not intended for any clinical use.